World's Best Scientists 2026 revealed!
Geoffrey I. Shapiro

Geoffrey I. Shapiro

D-Index & Metrics

Medicine

D-Index
121
Citations
65152
World Ranking
3563
National Ranking
1961

Geoffrey I. Shapiro publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Geoffrey I. Shapiro sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 595 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Geoffrey I. Shapiro D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Geoffrey I. Shapiro sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Geoffrey I. Shapiro is affiliated with Harvard University in the United States and has an extensive research portfolio primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. The main focus of their work lies in Oncology, Molecular Biology, and Pulmonary and Respiratory Medicine, covering a broad range of subfields including Cancer Research and Pathology and Forensic Medicine.

Shapiro's research topics encompass several key areas within cancer biology and treatment strategies. These include:

  • PARP inhibition in cancer therapy
  • DNA Repair Mechanisms
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer-related Molecular Pathways
  • Protein Degradation and Inhibitors
  • Lung Cancer Treatments and Mutations

Their recent publications demonstrate engagement with cutting-edge oncology topics, with papers such as:

  • "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors" (2020), published in the New England Journal of Medicine
  • "Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer" (2021), published in Cell
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020), published in Nature Medicine
  • "Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer" (2020), published in Nature Communications
  • "A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors" (2021), published in Nature Cancer

Their publication record includes frequent appearances in prominent journals such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • Nature Communications

Collaboration is a notable aspect of Shapiro's career, with frequent co-authors including:

  • Alan D. D'Andrea
  • Bose Kochupurakkal
  • James M. Cleary
  • Jennifer L. Guerriero
  • S. Percy Ivy

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

    D Li;L Ambrogio;L Ambrogio;T Shimamura;S Kubo

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Cyclin-dependent kinase pathways as targets for cancer treatment.

    Geoffrey I. Shapiro

  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Esra A. Akbay;Esra A. Akbay;Shohei Koyama;Julian Carretero;Abigail Altabef;Abigail Altabef

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • LKB1 modulates lung cancer differentiation and metastasis

    Hongbin Ji;Matthew R. Ramsey;D. Neil Hayes;Cheng Fan

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Targeting CDK4 and CDK6: From Discovery to Therapy

    Charles J. Sherr;David Beach;Geoffrey I. Shapiro

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

    Panagiotis A. Konstantinopoulos;Raphael Ceccaldi;Geoffrey I. Shapiro;Alan D. D'Andrea

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

    Jiehui Deng;Jiehui Deng;Eric S. Wang;Russell W. Jenkins;Shuai Li

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

    Amita Patnaik;Lee S. Rosen;Sara M. Tolaney;Anthony W. Tolcher

  • Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

    Leena Gandhi;D. Ross Camidge;Moacyr Ribeiro De Oliveira;Philip Bonomi

  • Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

    Charles M. Rudin;Christine L. Hann;Edward B. Garon;Moacyr Ribeiro de Oliveira

  • Anticancer drug targets: cell cycle and checkpoint control

    Geoffrey I. Shapiro;J. Wade Harper

Frequent Co-Authors

Patricia LoRusso
Patricia LoRusso Yale University
Sara M. Tolaney
Sara M. Tolaney Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
Alan D. D'Andrea
Alan D. D'Andrea Dana-Farber Cancer Institute
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Matthew Meyerson
Matthew Meyerson Harvard University
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of related online degrees and career pathways. Many students who aspire to work in healthcare choose alternative programs that align with their personal interests and career goals.

For those interested in the business and management side of healthcare, pursuing a best online healthcare administration degree can prepare you for leadership roles in hospitals, clinics, or health organizations. If you are a registered nurse seeking career advancement, consider the adn to fnp bridge programs—these flexible pathways help RNs become family nurse practitioners.

Passionate about nutrition and community health? An online nutritionist degree can lead to roles in wellness, education, and public health initiatives. For those aiming for high-level healthcare management, look for online mha programs cahme accredited, which ensure rigorous standards and broader career opportunities.

These online pathways offer flexibility, diverse career options, and the opportunity to impact patient care beyond traditional medical degrees.

Best Scientists Citing Geoffrey I. Shapiro

Trending Scientists

Recently Published Articles